Overactive Detrusor
16
1
2
10
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
2 terminated out of 16 trials
83.3%
-3.2% vs benchmark
19%
3 trials in Phase 3/4
30%
3 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (16)
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
Yoga for Treatment of Overactive Bladder in Pediatric Patients
Migraine Medication Effects on Urinary Symptoms
Minimizing Pain During Office Intradetrussor Botox Injection
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
Comparison of Different Treatments for Overactive Bladder Syndrome
Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia
Efficacy of Two Onabotulinum Toxin Doses
Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity
Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections
Reproductibility of Cystometry in Multiple Sclerosis Patient
Effects of Transcutaneous and Percutaneous PTNS on Idiopathic OAB
Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity
Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity
Onabotulinumtoxina Intradetrusorial Injections and NGF Expression
"Swallow my Urine Back" : Inhibition of Detrusor Overactivity by Swallowing Maneuver